Abstract: Despite the therapeutic advances made in the last decade, there remains a high unmet need for new cancer treatments. Recent approvals of Lutathera and Pluvicto has highlighted potential of of Radiopharmaceutical Therapy (RPT) as a safe and effective targeted modality for treatment of variety of solid tumors. Successful development of RPT requires a systematic optimization and rigorous evaluation of the targeting moiety, linker, chelator, and choice of radioisotopes. RayzeBio is leading innovation in this space by taking a systematic data driven drug discovery approach to identify best RPT agents against clinically validated oncology targets that have yet to drugged using RPT. RayzeBio approach has resulted in successful clinical advancement of RYZ101 (Ac225-DOTATATE) and a diverse pipeline of programs for which some pre-clinical data and RPT optimization strategies will be presented
.png)
